2018
Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials
Bhasin S, Ellenberg SS, Storer TW, Basaria S, Pahor M, Stephens-Shields AJ, Cauley JA, Ensrud KE, Farrar JT, Cella D, Matsumoto AM, Cunningham GR, Swerdloff RS, Wang C, Lewis CE, Molitch ME, Barrett-Connor E, Crandall JP, Hou X, Preston P, Cifelli D, Snyder PJ, Gill TM. Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials. The Lancet Diabetes & Endocrinology 2018, 6: 879-890. PMID: 30366567, PMCID: PMC6816466, DOI: 10.1016/s2213-8587(18)30171-2.Peer-Reviewed Original ResearchMeSH KeywordsAccidental FallsAgedClinical Trials as TopicHormone Replacement TherapyHumansMaleMobility LimitationTestosteroneTreatment OutcomeWalk TestWalkingConceptsEffects of testosteroneSelf-reported mobility limitationsPlacebo-treated menTestosterone-treated menLow testosterone concentrationsPlacebo groupMobility limitationsTestosterone concentrationsTestosterone groupTestosterone TrialsOlder menHemoglobin concentrationMin walk test distanceSelf-reported physical functionPlacebo gel dailyPatient Global ImpressionBaseline gait speedShort Form-36Total testosterone concentrationsPost-intervention assessmentModified intentionTreat populationTestosterone therapyTestosterone gelForm-36
2016
Effects of Testosterone Treatment in Older Men
Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, Barrett-Connor E, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Farrar JT, Cella D, Rosen RC, Pahor M, Crandall JP, Molitch ME, Cifelli D, Dougar D, Fluharty L, Resnick SM, Storer TW, Anton S, Basaria S, Diem SJ, Hou X, Mohler ER, Parsons JK, Wenger NK, Zeldow B, Landis JR, Ellenberg SS. Effects of Testosterone Treatment in Older Men. New England Journal Of Medicine 2016, 374: 611-624. PMID: 26886521, PMCID: PMC5209754, DOI: 10.1056/nejmoa1506119.Peer-Reviewed Original ResearchMeSH KeywordsAgedDepressionDouble-Blind MethodFatigueHormone Replacement TherapyHumansLibidoMaleProstate-Specific AntigenReference ValuesSexual BehaviorTestosteroneWalkingConceptsMid-normal rangeMen 65 yearsSerum testosterone concentrationsYears of ageTestosterone treatmentTestosterone levelsTestosterone concentrationsMen 19Depressive symptomsOlder menChronic Illness Therapy-Fatigue ScalePsychosexual Daily QuestionnaireSerum testosterone levelsPercentage of menAdverse eventsErectile functionPrimary outcomePlacebo gelSexual functionStudy groupWalking distanceFunctional assessmentMen ageModerate benefitDaily questionnaires